Web view
Journal Club from the Cochrane Library: Issue #65
Wiley
Cochrane club
Welcome to Issue #65 of Journal Club from the Cochrane Library
Issue #65 features a recently updated Cochrane Review from the Cochrane Eyes and Vision Group. The full version of this review is free-to-access for the next 30 days.

Every Journal Club email includes a Vignette and Discussion Questions slide deck. The fictional scenarios, we hope, will prove to be a valuable resource when running your own Journal Club or when teaching others how to critically appraise the evidence.

We have received some great feedback regarding the first issue of the new Journal Club. We’d love to continue to hear about how you use the Journal Club resources. Send us your feedback.
Read the Cochrane Review
Download the Vignette and Discussion Questions
Cochrane Review Summary
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis

The light-sensitive tissue at the back of the eye is known as the retina. The central area of the retina is called the macula. People with diabetes can develop problems in the retina, known as retinopathy. Some people with diabetic retinopathy can also develop oedema (swelling or thickening) at the macula. Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and can lead to visual loss.

One type of treatment for DMO is anti-vascular endothelial growth factor (anti-VEGF). This drug is given by means of an injection into the eye. It can reduce the swelling at the back of the eye and prevent visual loss. There are three main types of anti-VEGF drugs in use: aflibercept (EyeleaTM), bevacizumab (Avastin) and ranibizumab (LucentisTM). All three drugs are used to prevent visual loss and improve vision. They do this by slowing down the growth of new blood vessels and thereby reducing the swelling at the back of the eye. They may have adverse effects, particularly related to effects on blood vessels in the rest of the body. These effects may include stroke and heart attack.

The aim of this Cochrane Review was to find out which is the best type of anti-VEGF drug for DMO. Cochrane researchers collected and analysed all relevant studies to answer this question and found twenty-four studies including 6007 participants with DMO and moderate vision loss.

How did the effectiveness and safety of the different anti-VEGF drugs compare in preserving and improving vision and quality of life?
Read the free-to-access Cochrane Review.
From the Archive
Learn more about the Journal Club
Additional Resources
wileyblackwell
AMERICAS
John Wiley & Sons, Inc.
111 River Street,
Hoboken, NJ 07030-5774 USA
Phone: +1 877 762 2974

CANADA
John Wiley & Sons, Inc.
90 Eglinton Avenue East, Suite 300
Toronto, Ontario M4P 2Y3 Canada
Phone: +1 416 236 4433

EUROPE, MIDDLE EAST & AFRICA
John Wiley & Sons, Inc.
The Atrium Southern Gate,
Chichester, West Sussex PO19 8SQ England
Phone: +44 1243 843294
AUSTRALIA
John Wiley & Sons Pte Ltd
155 Cremorne Street,
Richmond, Victoria 3121 Australia
Phone: +61 07 3354 8444

ASIA
John Wiley & Sons Pte Ltd
1 Fusionopolis Walk,
#07-01 Solaris South Tower,
Singapore 138628
Phone: +65 6643 8333

Customer Service
Web: www.wiley.com/help
Email: wileycustomer@wiley.com
You are receiving this commercial e-mail message at mumoquit@cochrane.org
Update your subscription preferences   |   Unsubscribe

You may also unsubscribe by forwarding this email to e-service@wiley.com

© John Wiley & Sons. All rights reserved. Privacy Policy.
Wiley